Drug intelligence / Profile preview

bifidobacterium breve + lactobacillus acidophilus + lacticaseibacillus rhamnosus + saccharomyces boulardii + alpha amylase

Development stage
Unknown
Lead developer
Biohm Technologies
Modality
Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This is a **combination product** containing five active ingredients: bifidobacterium breve, lactobacillus acidophilus, lacticaseibacillus rhamnosus, saccharomyces boulardii, and alpha amylase. The first four components are probiotic microorganisms widely researched for their effects on gut health, modulation of immune responses, and prevention or treatment of various gastrointestinal disorders such as antibiotic-associated diarrhea, constipation, and irritable bowel syndrome[1][2][3][4][5]. Alpha amylase is an enzyme that participates in the breakdown of starches into simpler sugars, supporting digestive processes. The mechanisms of action for the probiotic species primarily involve restoration and maintenance of healthy gut microbiota, modulation of local and systemic immune responses, enhancement of mucosal barrier integrity, and antagonism against pathogenic bacteria. Saccharomyces boulardii, a non-pathogenic yeast, is notable for its ability to mitigate antibiotic-associated and infectious diarrhea and contribute to intestinal immune defenses[1][3][5]. The enzyme alpha amylase facilitates carbohydrate digestion, potentially supporting the function of the probiotics by improving nutrient availability.

Brand names
BIOHMBIOHM probioticBIOHM Total Gut ProbioticBIOHM FX Probiotic Blend
Other names
FX Probiotic Blend

Beyond the preview

Go deeper on bifidobacterium breve + lactobacillus acidophilus + lacticaseibacillus rhamnosus + saccharomyces boulardii + alpha amylase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium breve + lactobacillus acidophilus + lacticaseibacillus rhamnosus + saccharomyces boulardii + alpha amylase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call